Clinical studies have shown that tirzepatide: Significantly reduces hemoglobin A1C levels compared to placebo Promotes weight loss in a dose-dependent manner May have potential benefits for non-alcoholic fatty liver disease (NAFLD) patients Tirzepatide is typically administered as follows: Once-weekly subcutaneous injection Available in various strengths (e.g., 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) Dose is usually titrated over time to reach the target dose Common side effects may include: Nausea Diarrhea Decreased appetite Vomiting Constipation Abdominal pain Tirzepatide should be used with caution in patients with: History of pancreatitis Severe gastrointestinal disease Diabetic retinopathy Pregnancy: Tirzepatide should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus
Ozempic and Wegovy (both semaglutide) are single GLP-1 receptor agonists, while Zepbound and Mounjaro (both tirzepatide) are dual GLP-1/GIP agonists
Voting in favor of the measure were board members Jennifer Abbatacola, Sonia Garcia, Jon Gripe, Mohammad Iqbal, Bill Lenert, Anita Lewis, Bill Roth, Clifford Surges, Verner Tepe and David Young
10:e0140316
Vinciguerra F, Di Stefano C, Baratta R, et al
[] GLP-1
